(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
07 March 2024 (07.03.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/050439 A3

(51) International Patent Classification:
A61K 39/39 (2006.01) *C07K 16/32* (2006.01)
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2023/073194

(22) International Filing Date:
30 August 2023 (30.08.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/402,945 31 August 2022 (31.08.2022) US

(71) Applicants: **SYSTIMMUNE, INC.** [US/US]; 15318 NE 95th St, Redmond, Washington 98052 (US). **BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.** [CN/CN]; 139 Baili Road, Wenjiang District, Chengdu, Sichuan 611130 (CN).

(72) Inventors: **HELGESON, Luke A.**; 24240 SE 10th Pl., Sammamish, Washington 98075 (US). **ROZANITIS, Tyler C.**; 8501 Willows Road, Apt L268, Redmond, Washington 98052 (US). **GOULET, Dennis R.**; 6788 138th Ave NE #626, Redmond, Washington 98052 (US). **KHALILI, Jahan**; 12635 NE 130th Way #A103, Kirkland, Washington 98034 (US). **DAVIS, Nicholas S.**; 1425 Spring St. Apt 1406, Seatle, Washington 98104 (US). **ZHU, Yi**; 8-24, Building 6, No. 6, Lidu Road, Wuhou District, Chengdu, Sichuan (CN).

(74) Agent: **WAN, Feng**; EpiMED LLC, 10398 NE 17th St. Unit 306, Bellevue, Washington 98004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: BIEPITOPIC TETRAVALENT ANTIBODY TARGETING EGFR

FIG. 8B



	Separate		Mixed	
Antibody	EC50 EGFRwt (nM)	EC50 EGFRvIII (nM)	EC50 EGFRwt (nM)	EC50 EGFRvIII (nM)
SI-95X54	78.22	15.30	13.33	15.08

(57) Abstract: A biepitopic tetravalent antibody having a binding affinity to at least two epitopes of EGFR. The antibody comprises an antibody backbone and a scFv domain linked to the antibody backbone. The two epitopes of EGFR may include an EGFR wild-type (EGFRwt) epitope and an EGFRvIII epitope. The antibody has a stronger binding affinity to the EGFRvIII epitope than to the EGFRwt epitope.

WO 2024/050439 A3

[Continued on next page]

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
25 April 2024 (25.04.2024)